Genedrive Partners with Thermo Fisher Scientific to Launch High-Throughput CYP2C19 Pharmacogenetic Test

That is important because installed base matters in diagnostics. If hospitals and labs already use a platform, adding a new test can be much easier than persuading them to buy brand-new hardware first. In theory, that reduces adoption friction and broadens the commercial opportunity.

For retail investors, this looks like a sensible strategic move. Genedrive is not abandoning its point-of-care niche. It is trying to layer a lab-based revenue opportunity on top of it using an established platform partner.

Genedrive CYP2C19 HT Kit features show a clear pitch to busy genomic laboratories

The new kit is designed for high-throughput testing, meaning lots of samples can be processed per run. It uses the same clinically relevant allele panel as the current product – *2, *3, *4, *8, *17 and *35 – which genedrive says is intended to maximise ethnic inclusivity.

It is also configured as a multiplexed PCR reaction. That means several genetic targets can be checked in a single test run, which is usually a good thing for lab efficiency.

Another useful feature is that the kit is lyophilised, meaning freeze-dried for stability, and can be stored at ambient temperature. The company also says it works directly from blood without nucleic acid extraction, which should reduce workflow complexity, hands-on time and consumable use.

That may sound technical, but the commercial angle is straightforward: labs like tests that are quicker, simpler and cheaper to run. If genedrive can genuinely deliver that in practice, it improves the product’s appeal.

NICE guidance gives Genedrive a credible clinical backdrop in the UK stroke testing market

This announcement also leans on an important point: NICE, the National Institute for Health and Care Excellence, already recommends CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or TIA. NICE recommends laboratory-based testing, and also recommends the Genedrive CYP2C19 ID Kit for rapid point-of-care use when lab testing is not available.

That is a helpful position for genedrive. It means the company is not trying to create a brand-new clinical use case from scratch. The testing need is already recognised, and genedrive is now expanding its product range to match both parts of that pathway.

That does not guarantee sales, of course, but it does make the commercial conversation with NHS buyers more grounded than many early-stage diagnostics stories.

Key numbers from the Genedrive RNS that show the scale of the stroke and cardiovascular market

Metric	Figure
New stroke patients annually in the UK	Approximately 100,000
People living with the effects of stroke globally	Approximately 94 million
Global annual cost of stroke	$890 billion
US ischaemic strokes each year	Approximately 690,000
US TIAs each year	Approximately 240,000
US percutaneous coronary interventions each year	550,000

Those figures help explain why companies are interested in pharmacogenetic testing. Stroke and cardiovascular care are huge clinical areas, and even a small foothold in routine testing pathways could matter commercially.

What is positive in this Genedrive Thermo Fisher RNS – and what investors should still watch closely

The positives

• Broader market reach – genedrive can now target both near-patient and central laboratory testing.
• Strong platform partner – Thermo Fisher brings credibility and access to an existing diagnostic platform base.
• Guideline support – NICE already supports CYP2C19 testing in this setting.
• Operational appeal – direct-from-blood testing and ambient stability could suit busy labs.

The watchpoints

• No financial terms disclosed – the RNS does not say what the deal is worth.
• No revenue guidance disclosed – there are no forecasts for sales, margins or order timing.
• Still in development – the Genedrive CYP2C19 HT Kit is currently for performance evaluation only.
• Regulatory timing still ahead – UKCA certification is targeted for around the end of the 2026 calendar year, so commercial rollout is not immediate.

That last point is important. This is promising, but it is not the same as booked revenue. Investors should treat it as a strategic development agreement with potential, rather than proof of near-term financial upside.

Why Genedrive’s move into the NHS genomic laboratory market could reshape its product story

Up to now, genedrive’s story has leaned heavily on rapid point-of-care diagnostics. This deal adds a more scalable laboratory angle, which could make the company’s overall proposition more attractive.

If the point-of-care kit handles urgent cases and the high-throughput kit handles routine centralised volumes, genedrive can position itself as a more complete CYP2C19 testing provider. That is a better strategic narrative than relying on one format alone.

It also potentially strengthens the company’s standing with the NHS. Buyers often prefer solutions that fit real-world pathways, and real-world pathways are rarely one-size-fits-all.

My take on the Genedrive Thermo Fisher Scientific collaboration agreement

I think this is a genuinely positive RNS. Not because it delivers instant numbers – it does not – but because it makes strategic sense and addresses a clear gap in genedrive’s current offering.

The collaboration with Thermo Fisher gives genedrive a route into a different testing channel without abandoning its existing point-of-care niche. That is the kind of product expansion investors usually want to see from a small diagnostics company.

The caution is simple: the market should not get ahead of itself. There is no deal value, no sales forecast, and the product still needs to reach UKCA certification. So this is encouraging progress, not a finished commercial win.

Still, for a company of genedrive’s size, aligning with a global diagnostics name and targeting the UK NHS genomic laboratory market looks like a meaningful step forward. If execution follows, this could become a more important announcement than it first appears.